1. ALLA AKTIER
  2. NYHETER
  3. LUMITO

Lumito

Nyheter Lumito Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Lumito receives first order outside the Nordic region

MARKN.

Lumito AB (publ) (“Lumito” or the “Company”) has received an order from a European university hospital. The order, valued at approximately EUR 4,000, is the Company’s first order outside the Nordic region since its commercial launch and thus marks an initial commercial step into a new geographical market.

The order includes a SCIZYS Erbium Kit as well as scans through Scan-as-a-Service. The customer conducts cancer-related research at a university hospital and will use Lumito’s solution to evaluate the technology’s potential to provide increased sensitivity and improved tissue analysis compared with existing methods.

The order is a concrete result of Lumito’s work to evaluate AI-based methods for lead generation. The order confirms the Company’s ability to identify, engage with and convert identified business opportunities into commercial transactions.

"Our first commercial order outside the Nordic region is an encouraging step for Lumito. The order confirms both the international interest in SCIZYS and our ability to convert business opportunities into commercial transactions”, says Sanna Wallenborg, CEO of Lumito.

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Growth Market under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments
Lumito receives first order outside the Nordic region

Datum 2026-09-01, kl 10:30
Källa MFN
Bifogade filer
Lumito receives first order outside the Nordic region